nach oben

Current Gastroenterology Reports

Erschienen in:

01.06.2011

Current Approach to the Treatment of Achalasia

verfasst von: Joseph G. Cheatham, Roy K. H. Wong

Erschienen in: Current Gastroenterology Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Achalasia is a primary esophageal motility disorder characterized by aperistalsis and incomplete or absent relaxation of the lower esophageal sphincter (LES). The cause of the disease remains elusive and there is no intervention that improves the esophageal body function. Currently, treatment options focus on palliation of symptoms by reducing the LES pressure. The most effective and well-tolerated treatments continue to be the laparoscopic Heller myotomy and endoscopic pneumatic dilation; however, newer techniques (eg, peroral endoscopic myotomy and self-expanding metal stents) show promise. Botulinum toxin and pharmacologic therapy are reserved for those who are unable to undergo more effective therapies. Treatment options should be tailored to the patient, using current predictors of outcome such as the patient’s age and post-treatment LES pressures. The aim of this article is to highlight current literature and provide an up-to-date approach to the treatment of achalasia.

Mayberry JF. Epidemiology and demographics of achalasia. Gastrointest Endosc Clin N Am. 2001;11(2):235–48. v.PubMed

Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol. 2010;105(10):2144–9.PubMedCrossRef

Bortolotti M. Medical therapy of achalasia: a benefit reserved for few. Digestion. 1999;60(1):11–6.PubMedCrossRef

Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology. 1982;83(5):963–9.PubMed

Bortolotti M, Mari C, Lopilato C, et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology. 2000;118(2):253–7.PubMedCrossRef

Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50(6):758–64.PubMedCrossRef

Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995;332(12):774–8.PubMedCrossRef

Pasricha PJ, Rai R, Ravich WJ, et al. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110(5):1410–5.PubMedCrossRef

Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group Gut. 2000;46(5):597–600.

10.

Kolbasnik J, Waterfall WE, Fachnie B, et al. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol. 1999;94(12):3434–9.PubMedCrossRef

11.

D’Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis. 2002;34(2):105–10.PubMedCrossRef

12.

Tuset JA, Lujan M, Huguet JM, et al. Endoscopic pneumatic balloon dilation in primary achalasia: predictive factors, complications, and long-term follow-up. Dis Esophagus. 2009;22(1):74–9.PubMedCrossRef

13.

Kroupa R, Hep A, Dolina J, et al. Combined treatment of achalasia—botulinum toxin injection followed by pneumatic dilatation: long-term results. Dis Esophagus. 2010;23(2):100–5.PubMedCrossRef

14.

Vela MF, Richter JE, Khandwala F, et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol. 2006;4(5):580–7.PubMedCrossRef

15.

Radaelli F, Paggi S, Terreni N, et al. Acute reversible gastroparesis and megaduodenum after botulinum toxin injection for achalasia. Gastrointest Endosc. 2010;71(7):1326–7.PubMedCrossRef

16.

O’Connor JB, Singer ME, Imperiale TF, et al. The cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci. 2002;47(7):1516–25.PubMedCrossRef

17.

Vaezi MF, Richter JE. Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol. 1998;27(1):21–35.PubMedCrossRef

18.

Kadakia SC, Wong RK. Graded pneumatic dilation using Rigiflex achalasia dilators in patients with primary esophageal achalasia. Am J Gastroenterol. 1993;88(1):34–8.PubMed

19.

• Hulselmans M, Vanuytsel T, Degreef T, et al.: Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol. 2010;8(1):30–5. This study by Hulselmans et al. clearly outlines a successful pneumatic dilation technique based on a measured LES pressure endpoint that leads to long-term success rates. It also strongly substantiates prior findings that older populations are more likely to respond to pneumatic dilation and younger populations are likely to fail this therapeutic intervention. PubMedCrossRef

20.

Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg. 2009;249(1):45–57.PubMedCrossRef

21.

Zerbib F, Thetiot V, Richy F, et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol. 2006;101(4):692–7.PubMedCrossRef

22.

Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992;103(6):1732–8.PubMed

23.

Ponce J, Garrigues V, Pertejo V, et al. Individual prediction of response to pneumatic dilation in patients with achalasia. Dig Dis Sci. 1996;41(11):2135–41.PubMedCrossRef

24.

Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol. 2004;99(6):1029–36.PubMedCrossRef

25.

Sharma P, Kozarek R. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol. 2010;105(2):258–73. quiz 74.PubMedCrossRef

26.

Howard JM, Mongan AM, Manning BJ, et al. Outcomes in achalasia from a surgical unit where pneumatic dilatation is first-line therapy. Dis Esophagus. 2010;23(6):465–72.PubMedCrossRef

27.

Moawad FJ, Maydonovitch CL, Horwhat JD, Wong RK. Complications with pneumatic dilation. Clin Gastroenterol Hepatol. 2010;8(8):734–5. author reply 5.PubMedCrossRef

28.

Zhu YQ, Cheng YS, Tang GY, et al. Comparison of temporary stent insertion with pneumatic dilation of the same diameter in the treatment of achalasia patients: a retrospective study. J Gastroenterol Hepatol. 2010;25(3):499–505.PubMedCrossRef

29.

Zhao JG, Li YD, Cheng YS, et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience. Eur Radiol. 2009;19(8):1973–80.PubMedCrossRef

30.

Li YD, Cheng YS, Li MH, et al. Temporary self-expanding metallic stents and pneumatic dilation for the treatment of achalasia: a prospective study with a long-term follow-up. Dis Esophagus. 2010;23(5):361–7.PubMed

31.

De Palma GD, Lovino P, Masone S, et al. Self-expanding metal stents for endoscopic treatment of esophageal achalasia unresponsive to conventional treatments. Long-term results in eight patients. Endoscopy. 2001;33(12):1027–30.PubMedCrossRef

32.

Tsiaoussis J, Pechlivanides G, Gouvas N, et al. Patterns of esophageal acid exposure after laparoscopic Heller’s myotomy and Dor’s fundoplication for esophageal achalasia. Surg Endosc. 2008;22(6):1493–9.PubMedCrossRef

33.

Rebecchi F, Giaccone C, Farinella E, et al. Randomized controlled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: long-term results. Ann Surg. 2008;248(6):1023–30.PubMedCrossRef

34.

Boeckxstaens GE, Annese V, Bruley des Varannes S, et al. The European achalasia trial: a randomized multi-centre trial comparing endoscopic pneumodilation and laparoscopic myotomy as primary treatment of idiopathic achalasia. Gastroenterology. 2010;138(Supplemental 1):s53.

35.

Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotomies for esophageal achalasia: a single centre experience. Ann Surg. 2008;248(6):986–93.PubMedCrossRef

36.

Eldaif SM, Mutrie CJ, Rutledge WC, et al. The risk of esophageal resection after esophagomyotomy for achalasia. Ann Thorac Surg. 2009;87(5):1558–62. discussion 62–3.PubMedCrossRef

37.

• Inoue H, Minami H, Kobayashi Y, et al.: Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010;42(4):265–71. This study of a novel treatment for achalasia is the largest to date demonstrating excellent short-term outcomes from POEM and raising the expectations of positive results from larger studies with long-term outcomes.

38.

Perretta S, Dallemagne B, Allemann P, Marescaux J. Multimedia manuscript. Heller myotomy and intraluminal fundoplication: a NOTES technique. Surg Endosc. 2010;24(11):2903.PubMedCrossRef

Titel: Current Approach to the Treatment of Achalasia
verfasst von: Joseph G. Cheatham
Roy K. H. Wong
Publikationsdatum: 01.06.2011
Verlag: Current Science Inc.
Erschienen in: Current Gastroenterology Reports / Ausgabe 3/2011
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-011-0190-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Recent Progress in Congenital Diarrheal Disorders

Growth Assessment in Clinical Practice: Whose Growth Curve?

Intestinal Obstruction Syndromes in Cystic Fibrosis: Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Constipation

Ablative Therapies for Barrett’s Esophagus

Diagnosis of Eosinophilic Esophagitis: Current Approach and Future Directions